-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 23, Qin Wenxin’s team from Shanghai Cancer Research Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine published a long review in Nature Reviews Gastroenterology & Hepatology, and comprehensively summarized CRISPR.
Liver cancer is a malignant tumor involving multiple genes, mediated by multiple factors, and complicated pathological mechanisms
In recent years, with the rapid development and wide application of high-throughput sequencing technology, key gene mutations such as TERT promoter, TP53, CTNNB1, ARID1A, AXIN1, etc.
Although some breakthroughs have been made in the exploration of liver cancer treatment in the past ten years, it still faces the most urgent key problem in the field of liver cancer research: the lack of effective treatments for advanced liver cancer and the current standard therapies need to be further improved
The CRISPR-Cas9 functional gene screening technology screens and identifies genes related to tumorigenesis and development in a high-throughput manner, which has promoted the progress of cancer research
Researcher Qin Wenxin and Researcher Wang Cun of Shanghai Cancer Institute, Academician René Bernards of the Netherlands Cancer Institute are the co-corresponding authors of the review.
Link to the paper: https://